Intravenous to oral conversion of antihypertensives

A toolkit for guideline development

Joseph F. Dasta, Bradley Boucher, Gretchen M. Brophy, Henry Cohen, Erkan Hassan, Robert MacLaren, Karina Muzykovsky, Steven J. Martin, Steven E. Pass, Amy L. Seybert

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

OBJECTIVE: To provide a toolkit of information for hospitals to use in developing intravenous to oral conversion protocols for antihypertensives. DATA SOURCES: Articles describing intravenous to oral conversion protocols for any therapeutic category were identified in an English-language MEDLINE search (1990-April 2010) using a wide variety of MeSH terms. References from selected articles were reviewed for additional material. STUDY SELECTION AND DATA EXTRACTION: Experimental and observational English-language studies and review articles that focused on oral transition of intravenous drugs were selected. DATA SYNTHESIS: Most of the literature on conversion from intravenous to oral formulations involves antimicrobials. There is considerable evidence documenting reduced costs and improved patient flow through the health-care system following implementing these protocols with drugs like antimicrobials, histamine-2 receptor antagonists, and proton pump inhibitors. Although antihypertensives have not been studied, principles and implementation strategies used for other drug classes can be applied to antihypertensives. Guidance is provided on framing the problem, issues surrounding oral absorption principles, information pertaining to oral conversion in specific disease states, and implementation and documentation strategies. Detailed tables of oral and intravenous antihypertensives are provided. CONCLUSIONS: We recommend that hospitals consider developing protocols on conversion of intravenous to oral antihypertensives in an attempt to reduce unnecessarily prolonged intravenous therapy. Information contained in this article can be used as a toolkit to select information specific to the characteristics of individual health-care systems.

Original languageEnglish (US)
Pages (from-to)1430-1447
Number of pages18
JournalAnnals of Pharmacotherapy
Volume44
Issue number9
DOIs
StatePublished - Sep 1 2010

Fingerprint

Antihypertensive Agents
Guidelines
Language
Pharmaceutical Preparations
Delivery of Health Care
Histamine Receptors
Proton Pump Inhibitors
MEDLINE
Documentation
Costs and Cost Analysis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Dasta, J. F., Boucher, B., Brophy, G. M., Cohen, H., Hassan, E., MacLaren, R., ... Seybert, A. L. (2010). Intravenous to oral conversion of antihypertensives: A toolkit for guideline development. Annals of Pharmacotherapy, 44(9), 1430-1447. https://doi.org/10.1345/aph.1P086

Intravenous to oral conversion of antihypertensives : A toolkit for guideline development. / Dasta, Joseph F.; Boucher, Bradley; Brophy, Gretchen M.; Cohen, Henry; Hassan, Erkan; MacLaren, Robert; Muzykovsky, Karina; Martin, Steven J.; Pass, Steven E.; Seybert, Amy L.

In: Annals of Pharmacotherapy, Vol. 44, No. 9, 01.09.2010, p. 1430-1447.

Research output: Contribution to journalReview article

Dasta, JF, Boucher, B, Brophy, GM, Cohen, H, Hassan, E, MacLaren, R, Muzykovsky, K, Martin, SJ, Pass, SE & Seybert, AL 2010, 'Intravenous to oral conversion of antihypertensives: A toolkit for guideline development', Annals of Pharmacotherapy, vol. 44, no. 9, pp. 1430-1447. https://doi.org/10.1345/aph.1P086
Dasta, Joseph F. ; Boucher, Bradley ; Brophy, Gretchen M. ; Cohen, Henry ; Hassan, Erkan ; MacLaren, Robert ; Muzykovsky, Karina ; Martin, Steven J. ; Pass, Steven E. ; Seybert, Amy L. / Intravenous to oral conversion of antihypertensives : A toolkit for guideline development. In: Annals of Pharmacotherapy. 2010 ; Vol. 44, No. 9. pp. 1430-1447.
@article{96f1131c9d1f4f21a03d27c411a2ab2a,
title = "Intravenous to oral conversion of antihypertensives: A toolkit for guideline development",
abstract = "OBJECTIVE: To provide a toolkit of information for hospitals to use in developing intravenous to oral conversion protocols for antihypertensives. DATA SOURCES: Articles describing intravenous to oral conversion protocols for any therapeutic category were identified in an English-language MEDLINE search (1990-April 2010) using a wide variety of MeSH terms. References from selected articles were reviewed for additional material. STUDY SELECTION AND DATA EXTRACTION: Experimental and observational English-language studies and review articles that focused on oral transition of intravenous drugs were selected. DATA SYNTHESIS: Most of the literature on conversion from intravenous to oral formulations involves antimicrobials. There is considerable evidence documenting reduced costs and improved patient flow through the health-care system following implementing these protocols with drugs like antimicrobials, histamine-2 receptor antagonists, and proton pump inhibitors. Although antihypertensives have not been studied, principles and implementation strategies used for other drug classes can be applied to antihypertensives. Guidance is provided on framing the problem, issues surrounding oral absorption principles, information pertaining to oral conversion in specific disease states, and implementation and documentation strategies. Detailed tables of oral and intravenous antihypertensives are provided. CONCLUSIONS: We recommend that hospitals consider developing protocols on conversion of intravenous to oral antihypertensives in an attempt to reduce unnecessarily prolonged intravenous therapy. Information contained in this article can be used as a toolkit to select information specific to the characteristics of individual health-care systems.",
author = "Dasta, {Joseph F.} and Bradley Boucher and Brophy, {Gretchen M.} and Henry Cohen and Erkan Hassan and Robert MacLaren and Karina Muzykovsky and Martin, {Steven J.} and Pass, {Steven E.} and Seybert, {Amy L.}",
year = "2010",
month = "9",
day = "1",
doi = "10.1345/aph.1P086",
language = "English (US)",
volume = "44",
pages = "1430--1447",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "9",

}

TY - JOUR

T1 - Intravenous to oral conversion of antihypertensives

T2 - A toolkit for guideline development

AU - Dasta, Joseph F.

AU - Boucher, Bradley

AU - Brophy, Gretchen M.

AU - Cohen, Henry

AU - Hassan, Erkan

AU - MacLaren, Robert

AU - Muzykovsky, Karina

AU - Martin, Steven J.

AU - Pass, Steven E.

AU - Seybert, Amy L.

PY - 2010/9/1

Y1 - 2010/9/1

N2 - OBJECTIVE: To provide a toolkit of information for hospitals to use in developing intravenous to oral conversion protocols for antihypertensives. DATA SOURCES: Articles describing intravenous to oral conversion protocols for any therapeutic category were identified in an English-language MEDLINE search (1990-April 2010) using a wide variety of MeSH terms. References from selected articles were reviewed for additional material. STUDY SELECTION AND DATA EXTRACTION: Experimental and observational English-language studies and review articles that focused on oral transition of intravenous drugs were selected. DATA SYNTHESIS: Most of the literature on conversion from intravenous to oral formulations involves antimicrobials. There is considerable evidence documenting reduced costs and improved patient flow through the health-care system following implementing these protocols with drugs like antimicrobials, histamine-2 receptor antagonists, and proton pump inhibitors. Although antihypertensives have not been studied, principles and implementation strategies used for other drug classes can be applied to antihypertensives. Guidance is provided on framing the problem, issues surrounding oral absorption principles, information pertaining to oral conversion in specific disease states, and implementation and documentation strategies. Detailed tables of oral and intravenous antihypertensives are provided. CONCLUSIONS: We recommend that hospitals consider developing protocols on conversion of intravenous to oral antihypertensives in an attempt to reduce unnecessarily prolonged intravenous therapy. Information contained in this article can be used as a toolkit to select information specific to the characteristics of individual health-care systems.

AB - OBJECTIVE: To provide a toolkit of information for hospitals to use in developing intravenous to oral conversion protocols for antihypertensives. DATA SOURCES: Articles describing intravenous to oral conversion protocols for any therapeutic category were identified in an English-language MEDLINE search (1990-April 2010) using a wide variety of MeSH terms. References from selected articles were reviewed for additional material. STUDY SELECTION AND DATA EXTRACTION: Experimental and observational English-language studies and review articles that focused on oral transition of intravenous drugs were selected. DATA SYNTHESIS: Most of the literature on conversion from intravenous to oral formulations involves antimicrobials. There is considerable evidence documenting reduced costs and improved patient flow through the health-care system following implementing these protocols with drugs like antimicrobials, histamine-2 receptor antagonists, and proton pump inhibitors. Although antihypertensives have not been studied, principles and implementation strategies used for other drug classes can be applied to antihypertensives. Guidance is provided on framing the problem, issues surrounding oral absorption principles, information pertaining to oral conversion in specific disease states, and implementation and documentation strategies. Detailed tables of oral and intravenous antihypertensives are provided. CONCLUSIONS: We recommend that hospitals consider developing protocols on conversion of intravenous to oral antihypertensives in an attempt to reduce unnecessarily prolonged intravenous therapy. Information contained in this article can be used as a toolkit to select information specific to the characteristics of individual health-care systems.

UR - http://www.scopus.com/inward/record.url?scp=77956237270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956237270&partnerID=8YFLogxK

U2 - 10.1345/aph.1P086

DO - 10.1345/aph.1P086

M3 - Review article

VL - 44

SP - 1430

EP - 1447

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 9

ER -